Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$heff, sincere congratulations on an honor and recognition well deserved on your part. Thanks again for all you do.
SGMO-$7.94. Chart looking good.
ASTM- macd crossover today.
SRZ-Sunrise Senior Living ($7.51) breaking out of 1 week consolidation.
SGMO-Sangamo BioSciences($7.66) broke out of base yesterday.
ACHN-Achillion Pharmaceuticals. 5 analysts rate it strong buy, 2 analysts rate it a buy with a pt of $6.25.
Data provided by Capital IQ, except where noted.
Financial Highlights
Fiscal Year
Fiscal Year Ends: Dec 31
Most Recent Quarter (mrq): Sep 30, 2010
Profitability
Profit Margin (ttm): N/A
Operating Margin (ttm): -5,227.64%
Management Effectiveness
Return on Assets (ttm): -39.05%
Return on Equity (ttm): -82.35%
Income Statement
Revenue (ttm): 492.00K
Revenue Per Share (ttm): 0.01
Qtrly Revenue Growth (yoy): N/A
Gross Profit (ttm): -294.00K
EBITDA (ttm): -24.81M
Net Income Avl to Common (ttm): -25.96M
Diluted EPS (ttm): -0.70
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 62.16M
Total Cash Per Share (mrq): 1.07
Total Debt (mrq): 1.64M
Total Debt/Equity (mrq): 2.94
Current Ratio (mrq): 9.67
Book Value Per Share (mrq): 0.96
Cash Flow Statement
Operating Cash Flow (ttm): -23.15M
Levered Free Cash Flow (ttm): -15.72M
View Financials
Income Statement - Balance Sheet - Cash Flow
Trading Information
Stock Price History
Beta: 0.37
52-Week Change3: 38.78%
S&P500 52-Week Change3: 12.17%
52-Week High (Jan 11, 2011)3: 4.38
52-Week Low (May 21, 2010)3: 1.99
50-Day Moving Average3: 3.34
200-Day Moving Average3: 2.88
Share Statistics
Avg Vol (3 month)3: 116,223
Avg Vol (10 day)3: 177,129
Shares Outstanding5: 58.35M
Float: 34.94M
% Held by Insiders6: 79.82%
% Held by Institutions6: 47.30%
Shares Short (as of Dec 15, 2010)3: 189.49K
Short Ratio (as of Dec 15, 2010)3: 2.50
Short % of Float (as of Dec 15, 2010)3: 0.70%
Shares Short (prior month)3: 200.06K
Link to
http://seekingalpha.com/article/244145-what-s-next-for-achillion-pharma?source=yahoo
RGEN-Repligen Corp. 1 analyst has a strong buy on it with a pt of $9.
Data provided by Capital IQ, except where noted.
Income Statement
Revenue (ttm): 24.81M
Revenue Per Share (ttm): 0.81
Qtrly Revenue Growth (yoy): 34.80%
Gross Profit (ttm): 15.46M
EBITDA (ttm): 1.17M
Net Income Avl to Common (ttm): -366.90K
Diluted EPS (ttm): -0.01
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 56.43M
Total Cash Per Share (mrq): 1.83
Total Debt (mrq): 0.00
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 17.17
Book Value Per Share (mrq): 2.22
Cash Flow Statement
Operating Cash Flow (ttm): 1.66M
Levered Free Cash Flow (ttm): 657.92K
View Financials
Income Statement - Balance Sheet - Cash Flow
Trading Information
Stock Price History
Beta: 0.73
52-Week Change3: 21.29%
S&P500 52-Week Change3: 12.17%
52-Week High (Dec 29, 2010)3: 4.85
52-Week Low (May 25, 2010)3: 3.00
50-Day Moving Average3: 4.15
200-Day Moving Average3: 3.61
Share Statistics
Avg Vol (3 month)3: 49,423
Avg Vol (10 day)3: 76,271
Shares Outstanding5: 30.79M
Float: 25.44M
% Held by Insiders6: 11.04%
% Held by Institutions6: 41.60%
Shares Short (as of Dec 15, 2010)3: 253.88K
Short Ratio (as of Dec 15, 2010)3: 5.70
Short % of Float (as of Dec 15, 2010)3: 1.00%
Shares Short (prior month)3: 256.82K
Link to
http://seekingalpha.com/article/243440-repligen-s-promising-potential-in-2011?source=yahoo
NPSP, RGEN, SGMO, ZIOP all moving well today.
Picked up some more AVNR and a little ASTM this a.m.
Anyone familiar with NPSP? 5 analysts have it rated a strong buy. 154.2 mil cash, 87.9% institutional ownership.
DEPO and OSUR charts look very similar. Nice slow climb.
Thanks for the info. GLTU
Interesting that HDY is on this list. Shorts and mm's pulled a bear raid on HDY friday. At 10:52 pps was 6.62, by 11:08 pps was 5.53, by 11:20 pps was 6.30 and closed up on the day 2.77%.
I'm in OSUR. It is up.
AVNR is a good example of a bear raid. Take a look at that chart. Someone wanted shares of this cheap plus shorts doing some covering.
Looked like a bear raid to me. JMO
$heff, does ADLR have anything in the pipeline
Float:41.67 mil
SO: 46.39 mil
Inst. ownership: 63.7%
Total cash: 53.59 mil
Took a starter position in PLX @ 10.05.
$heff you posted an article about "bunion toe" I believe it was. I can't find the post. Do you remember which post it was? TIA
Happy New Year to $heff's Station. Great board and people. Thanks to this board for a profitable 2010. Let's do the same in 2011. This board changes peoples' futures, love it.
FTK(5.23) green on a red day.
FTK-Flotek Industries(4.78). I know this isn't biotech but the chart is outstanding and worth a look. Appears to be ready breakout. I have no position in this stock, but am watching it tomorrow. GLTA
ACHN-Achillion Pharmaceuticals. This stock has moved up quietly from a low of $2.50 to a high of $4.11 in the last 3 weeks. What's up with this company? Institutional ownership 47.3%, insiders own 79.82%. 34.94 mil float. 62.16 mil cash.
$heff, good article on DEPO CEO interview. Thanks.
I like this article, good points made. I posted this same article on this board on Dec. 23 and received a response saying "this might be the silliest thing Seeking Alpha has ever posted."
ASTM @ 2.48
$6.40 for resistance on 10/09/2009.
Thanks $heff, good advice. I was in @ 1.76 and out @ 1.96. Quick trade for 11%.
Took a starter position in BPAX(1.90) @ 1.76
I guess time will tell. I don't know. And I'm not saying I agree with the article. I just posted it. But if it were buy and sell and buy and sell that is for profit, but there was not much selling at the close. Just tring to figure it out. Nobody seems to have THE answer, just answers.
IMO, if that were the case I would think momo players would take their profit rather than hold over a long weekend. XOMA did not selloff though. Who knows. I appreciate your opinions. Have a Happy Holiday.
Xoma; from Seeking Alpha
Xoma (XOMA) soared yesterday on no news from the company. Early afternoon, Reuters put out a press release stating that the rally occurred on high expectations of the mid-stage results of XOMA 052 in the treatment of diabetes.
Surprised by XOMA’s rally, many asked if we heard news that could be behind XOMA’s rally. We were surprised by their surprise more than by the stock’s move. The reasons for XOMA’s soaring at this stage could only be one of the following; good news expected to come from XOMA 052’s clinical trials; the appearance of a prospective deep-pocketed drug company that seeks partnership on XOMA 052, offering Xoma multimillion dollars in upfront payment; or an upgrade coming from a heavyweight analyst.
Investors know that XOMA 052, a monoclonal antibody inhibitor of interleukin-1 (IL-1), is in various trials for Type 1 and Type 2 diabetes and for many other diseases of inflammatory origin. They know that Phase I trial results on diabetes were better than endocrinologists expected and that the drug is safe. More important is that they know that proof of concept has been already offered in studies conducted on the impact inhibiting IL-1 on diabetes and other diseases. So the rally in the stock should not surprise anybody.
After years of disappointments and seeing their money evaporate, Xoma’s shareholders developed a hard-to-reverse distrust in the firm’s management. They reached a stage of disappointment with the firm that led them to be convinced that no matter how good XOMA 052 could be, the drug will never see the light of day to benefit Xoma’s shareholders. Isn’t Xoma known to contribute its technologies and expertise to benefit other firms with almost no benefit to itself?
This skepticism, we believe, is not realistic. First of all, the current management inherited mistakes made in the past. Secondly, the drug is very promising and the data from experimentation by Xoma and others confirm that efficient inhibition of IL-1 could be a unique treatment for diabetes and chronic inflammatory diseases that affect various systems, cells and organs. Xoma is almost finishing Phase II trials and a successful outcome would easily bring a partner ready to pay a huge upfront payment that can change the firm’s life from that time on.
A proof of concept for Xoma 052 came at the hands of scientists who hypothesized that diabetes, like autoimmune diseases, starts with inflammation that causes destruction of the beta cells of the pancreas. In a study, patients with Type 2 diabetes, patients given Anakinra, an IL-1 blocker developed by Amgen and approved for rheumatoid arthritis had improved glycated hemoglobin (HbA1c) levels, insulin production, blood sugar control and pancreatic beta cell function. A second follow up study demonstrated that nine months after final treatment with anakinra, insulin usage was reduced by 67 percent among patients who had responded to the drug during the initial 13-week dosing study.
The results of the study suggest that the IL-1 antagonist has the potential to modify Type 2 diabetes by preserving insulin-producing cells, not just control the disease symptoms. On the other hand, most current medications used in type 2 diabetes work through either boosting insulin secretion by the pancreas, increasing the cells’ sensitivity to insulin, or using of insulin as replacement therapy. They do not go to the root cause of the disease like IL-1 blockers, especially Xoma 052, which has several advantages over other available IL-1 antagonists.
If these test results and the results of Phase 1 trials on XOMA 052 are confirmed in the current trials’ results, the drug will be the first cytokine inhibitor to be used in the treatment of Type 1 and Type 2 diabetes.
XOMA 052 is also in trials for cardiovascular disease, rheumatoid arthritis, acute gout, systemic juvenile idiopathic arthritis (sJIA) and Behcet’s uveitis. Recently, positive results came from an open-label pilot study of XOMA 052 in patients with Behcet’s uveitis who were suffering from vision-threatening exacerbations after receiving maximal doses of immunosuppressive medicines. All the patients (seven) experienced rapid reduction of intraocular inflammation and improvement in visual acuity and other ophthalmic measures following a single treatment. New results demonstrate that each of five patients re-treated with XOMA 052 due to recurrent uveitis exacerbation responded again to XOMA 052 treatment and maintained their response for several months. A cytokine study results showed a reduction in the levels of IL-1 beta, IL-1 alpha and IL-6 and increased levels of interferon gamma. The increase in interferon gamma is considered favorable, as it protects from infection. The FDA has granted XOMA 052, an orphan drug for Behcet's disease and so did the European Medicinal Agency.
Behcet's disease causes vasculitis (chronic inflammation of the blood vessels) and major symptoms affecting the neurological, pulmonary, gastrointestinal and cardiovascular systems. Complications include painful ulcers in the mouth and on the genitals. The disease is most common among people from countries along this ancient trade route, the Silk Road, including Turkey, eastern Mediterranean countries, Japan and Korea. That’s why it is referred to as the “Silk Road disease”
Uveitis is an inflammation of the intraocular tissues of the eye. Uveitis complicating Behcet’s Disease, also called Behcet’s uveitisis a very severe form of uveitis. It affects half of Behcet's disease patients. Unlike many forms of chronic uveitis, Behcet's uveitis is characterized by frequent recurrence of acute attacks or exacerbations. Without immediate treatment, major exacerbations of Behcet's uveitis may lead to retinal detachment, vitreous hemorrhage, glaucoma and blindness. Accumulation of vitreous haze can block the vision or cause the loss of visual acuity. Patients can go from 20/20 eyesight to blindness during one course of exacerbation.
Treatments for Behcet's uveitis are currently limited to corticosteroids and off-label use of immunosuppressive chemotherapeutic drugs, which have significant side effects when used for long.
Why Xoma 052?
XOMA 052 is a Human Engineered IgG2 antibody with a half-life of 22 days. It has an ultra high binding affinity for IL-1? - a pro-inflammatory cytokine believed to be a leading cause of inflammation. By binding IL-1?, XOMA 052 modulates the activation of the IL-1 receptor, thus interferes with the cellular signaling that instigate the inflammatory responses. Based on its combined pharmacokinetic and binding properties, XOMA 052 may provide dosing of once per one month or longer. This is an important advantage over other drugs that target IL-1. Anakinra, for example, requires daily injections that frequently involve mild but painful injection site reactions.
Xoma has a great technology that can breed many effective products for diseases with unmet medical needs. The scientists have done a great job, creating a technology that develops competitive products. Through these technologies, Xoma has contributed to the successful development of many important products, but for other companies. It has attracted many firms, including several large pharmaceutical companies to license Xoma’s technologies. The only problem was past inefficient managements, which committed many mistakes that devastated Xoma and its shareholders for years.
We hope that the current management would be successful this time in signing agreements favorable to Xoma. We believe it will and as a result, we see a real chance for Xoma to turn from a loser to one of the most successful biotech firms worth its scientists efforts and advanced technologies. Are we optimistic? The answer is Yes.
Merry Christmas and Happy New Year to all at $heff's Station. May all of you and your loved ones enjoy the Holidays together. God bless all of us. It's been a rewarding year here. Let's carry this on into the New Year.
NLTX- need to see it stay above 200 day sma(.60)
RPRX(2.10)
11:05AM Repros Therapeutics submits data to the FDA supporting morning assessment of testosterone for men treated with Androxal (RPRX) 1.63 +0.20 : Co announced it has submitted to the FDA data collected from three different studies which the Company believes demonstrates that the assessment of testosterone levels between 8 and 10 in the morning is indicative of the maximum and average levels of the male hormone achieved during a particular day following the administration of Androxal
Thanks WI Biker. Glad to be able to contribute to this excellent board.
Back in CAPS @ .52
ANX- broke out of base three days ago. Needs to close above resistance at 3.01
AEZS- nice chart. Broke out of base 5 days ago. Resistance at 2.19